Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH.

J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.

PMID:
31085763
2.

The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.

Cloyd JM, Konda B, Shah MH, Pawlik TM.

Expert Rev Clin Pharmacol. 2019 Feb;12(2):101-108. doi: 10.1080/17512433.2019.1561273. Epub 2019 Jan 16. Review.

PMID:
30582383
3.

The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.

Nguyen MC, Shah MH, Liebner DA, Backes FJ, Phay J, Shirley LA.

J Natl Compr Canc Netw. 2018 Nov;16(11):1279-1283. doi: 10.6004/jnccn.2018.7059.

PMID:
30442730
4.

Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.

Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B.

J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040. doi: 10.6004/jnccn.2018.7043.

PMID:
30181415
5.

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.

PMID:
29891520
6.

Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.

Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1277-1281. doi: 10.1210/jc.2017-02533.

7.

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.

Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, Abdel-Misih SRZ, Dillhoff ME, Sipos JA, Kirschner LS, Shah MH.

Oncotarget. 2017 Oct 24;8(61):104046-104056. doi: 10.18632/oncotarget.22001. eCollection 2017 Nov 28.

8.

Favorable and Durable Response to Pazopanib in Metastatic Refractory Paraganglioma.

Patel S, Owen D, Schmidt CR, Kirschner LS, Phay J, Shirley L, Dillhoff M, Brock P, Espinosa A, Shah MH, Konda B.

J Oncol Pract. 2017 Dec;13(12):840-842. doi: 10.1200/JOP.2017.024984. Epub 2017 Aug 29. No abstract available.

PMID:
28850312
9.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

10.

Endocrine dysfunction following immune checkpoint inhibitor therapy.

Konda B, Nabhan F, Shah MH.

Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):337-347. doi: 10.1097/MED.0000000000000357. Review.

PMID:
28661915
11.

Transforming Growth Factor β1-Induced NADPH Oxidase-4 Expression and Fibrotic Response in Conjunctival Fibroblasts.

Brown KD, Shah MH, Liu GS, Chan EC, Crowston JG, Peshavariya HM.

Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3011-3017. doi: 10.1167/iovs.16-20633.

PMID:
28605812
12.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI.

Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3.

13.

Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?

Kitano M, Davidson GW, Shirley LA, Schmidt CR, Guy GE, Khabiri H, Dowell JD, Shah MH, Bloomston M.

Ann Surg Oncol. 2016 Nov;23(12):4008-4015. Epub 2016 Jul 8.

PMID:
27393568
14.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ.

Oncology. 2016;90(6):339-46. doi: 10.1159/000445978. Epub 2016 May 21.

15.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ.

Invest New Drugs. 2016 Jun;34(3):290-9. doi: 10.1007/s10637-016-0336-9. Epub 2016 Mar 9.

16.

Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.

Haraldsdottir S, Bertino E, Haglund K, Kaffenberger B, Shah MH.

JAMA Dermatol. 2016 May 1;152(5):587-9. doi: 10.1001/jamadermatol.2015.5366. No abstract available.

PMID:
26886900
17.

Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.

Onesti JK, Shirley LA, Saunders ND, Davidson GW, Dillhoff ME, Khabiri H, Guy GE, Dowell JD, Schmidt CR, Shah MH, Bloomston M.

J Gastrointest Surg. 2016 Mar;20(3):580-6. doi: 10.1007/s11605-015-2998-6. Epub 2015 Oct 21.

PMID:
26489743
18.

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI.

Clin Cancer Res. 2016 Jan 1;22(1):44-53. doi: 10.1158/1078-0432.CCR-15-1127. Epub 2015 Aug 26.

19.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

20.

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.

Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW.

Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24.

21.

Differential effects of superoxide dismutase and superoxide dismutase/catalase mimetics on human breast cancer cells.

Shah MH, Liu GS, Thompson EW, Dusting GJ, Peshavariya HM.

Breast Cancer Res Treat. 2015 Apr;150(3):523-34. doi: 10.1007/s10549-015-3329-z. Epub 2015 Mar 21.

PMID:
25794772
22.

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.

N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.

23.

Neuroendocrine tumors, version 1.2015.

Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Jan;13(1):78-108.

PMID:
25583772
24.

Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.

Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R.

Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262.

25.

Bone metastases and skeletal-related events from neuroendocrine tumors.

Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK.

Endocr Connect. 2015 Mar;4(1):9-17. doi: 10.1530/EC-14-0119. Epub 2014 Nov 27.

26.

Smad-independent pathway involved in transforming growth factor β1-induced Nox4 expression and proliferation of endothelial cells.

Hakami NY, Wong H, Shah MH, Dusting GJ, Jiang F, Peshavariya HM.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Mar;388(3):319-26. doi: 10.1007/s00210-014-1070-5. Epub 2014 Nov 27.

PMID:
25428269
27.

Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center.

Kavecansky J, Wei L, Caronia L, Ramirez MT, Bloomston M, Shah MH.

Pancreas. 2015 Mar;44(2):198-203. doi: 10.1097/MPA.0000000000000267.

PMID:
25411805
28.

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.

Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD.

Horm Cancer. 2014 Aug;5(4):232-9. doi: 10.1007/s12672-014-0182-1. Epub 2014 May 22. Erratum in: Horm Cancer. 2014 Dec;5(6):424. Hasseltine, Elizabeth A [corrected to Hesseltine, Elizabeth A].

29.

New era for treatment in differentiated thyroid cancer.

Haraldsdottir S, Shah MH.

Lancet. 2014 Jul 26;384(9940):286-8. doi: 10.1016/S0140-6736(14)60663-2. Epub 2014 Apr 24. No abstract available.

PMID:
24768111
30.

An update on clinical trials of targeted therapies in thyroid cancer.

Haraldsdottir S, Shah MH.

Curr Opin Oncol. 2014 Jan;26(1):36-44. doi: 10.1097/CCO.0000000000000029. Review.

PMID:
24240178
31.

Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.

32.

Thyroid cancer: pathogenesis and targeted therapy.

Liebner DA, Shah MH.

Ther Adv Endocrinol Metab. 2011 Oct;2(5):173-95. doi: 10.1177/2042018811419889.

33.

American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce.

Thyroid. 2012 Nov;22(11):1104-39. doi: 10.1089/thy.2012.0302.

PMID:
23130564
34.

Liver-directed therapies in patients with advanced neuroendocrine tumors.

Jones NB, Shah MH, Bloomston M.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):765-74. Review.

PMID:
22679118
35.

Neuroendocrine tumors.

Kulke MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):724-64.

PMID:
22679117
36.

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG.

Clin Cancer Res. 2012 Jun 1;18(11):3170-9. doi: 10.1158/1078-0432.CCR-11-3005.

37.

Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.

Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, Salem R.

J Vasc Interv Radiol. 2012 May;23(5):669-74. doi: 10.1016/j.jvir.2012.01.059. Review.

PMID:
22525023
38.

Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists.

Colevas AD, Shah MH.

Am Soc Clin Oncol Educ Book. 2012:384-8. doi: 10.14694/EdBook_AM.2012.32.384.

39.

Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.

Koh YW, Shah MH, Agarwal K, McCarty SK, Koo BS, Brendel VJ, Wang C, Porter K, Jarjoura D, Saji M, Ringel MD.

Endocr Relat Cancer. 2012 Jan 9;19(1):29-38. doi: 10.1530/ERC-11-0155. Print 2012 Feb.

40.

Role of BRAF in thyroid oncogenesis.

Caronia LM, Phay JE, Shah MH.

Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Epub 2011 Sep 7. Review.

41.

Unusual metastases of gastrointestinal stromal tumor and genotypic correlates: Case report and review of the literature.

Abuzakhm SM, Acre-Lara CE, Zhao W, Hitchcock C, Mohamed N, Arbogast D, Shah MH.

J Gastrointest Oncol. 2011 Mar;2(1):45-9. doi: 10.3978/j.issn.2078-6891.2011.006. No abstract available.

42.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

43.

A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.

Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH.

Invest New Drugs. 2012 Apr;30(2):629-38. doi: 10.1007/s10637-010-9563-7. Epub 2010 Oct 12.

44.

Targeting RET receptor tyrosine kinase activation in cancer.

Phay JE, Shah MH.

Clin Cancer Res. 2010 Dec 15;16(24):5936-41. doi: 10.1158/1078-0432.CCR-09-0786. Epub 2010 Oct 7. Review.

45.

Prospects for small interfering RNA therapeutics in thyroid cancer.

Jhiang SM, Shah MH.

Thyroid. 2010 Oct;20(10):1049-50. doi: 10.1089/thy.2010.1660. No abstract available.

PMID:
20883169
46.

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH.

J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5.

47.

Thyroid cancer: emerging role for targeted therapies.

Sipos JA, Shah MH.

Ther Adv Med Oncol. 2010 Jan;2(1):3-16. doi: 10.1177/1758834009352667.

48.

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium.

Blood. 2010 Apr 15;115(15):3008-16. doi: 10.1182/blood-2009-08-231613. Epub 2009 Dec 18.

49.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.

J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23.

50.

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.

Clin Cancer Res. 2009 Sep 15;15(18):5869-77. doi: 10.1158/1078-0432.CCR-08-2480. Epub 2009 Sep 8.

Supplemental Content

Loading ...
Support Center